Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study.

Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, Vanderstichele A, Agreiter C, Harter P, Obermayr E, Vergote I, Zeillinger R, Speiser P.

Int J Gynecol Cancer. 2018 Nov;28(9):1692-1698. doi: 10.1097/IGC.0000000000001361.

PMID:
30376484
2.

Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates.

Maritschnegg E, Heinzl N, Wilson S, Deycmar S, Niebuhr M, Klameth L, Holzer B, Koziel K, Concin N, Zeillinger R.

Anal Chem. 2018 Nov 20;90(22):13273-13279. doi: 10.1021/acs.analchem.8b02373. Epub 2018 Oct 29.

PMID:
30277755
3.

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer.

Svoboda M, Mungenast F, Gleiss A, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Jäger W, Mechtcheriakova D, Cacsire-Tong D, Zeillinger R, Thalhammer T, Pils D.

Front Pharmacol. 2018 Aug 7;9:842. doi: 10.3389/fphar.2018.00842. eCollection 2018.

4.

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2018 Apr 17;13(4):e0196142. doi: 10.1371/journal.pone.0196142. eCollection 2018.

5.

Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.

Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R.

Gynecol Oncol. 2018 May;149(2):371-380. doi: 10.1016/j.ygyno.2018.02.020. Epub 2018 Mar 9.

PMID:
29530331
6.

Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells.

Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, Helmy-Bader S, Danzinger S, Krainer M, Singer C, Zeillinger R.

Oncotarget. 2017 Nov 28;9(1):812-823. doi: 10.18632/oncotarget.22549. eCollection 2018 Jan 2.

7.

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B.

Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5.

8.

PARP inhibition causes premature loss of cohesion in cancer cells.

Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.

Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28.

9.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017. Erratum in: PLoS One. 2018 Apr 17;13(4):e0196142.

10.

Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA.

Kriegshäuser G, Enko D, Zitt M, Oberwalder M, Oberkanins C, Öfner D, Zeillinger R, Maximilian Müller H.

Int J Biol Markers. 2017 Oct 31;32(4):e467-e470. doi: 10.5301/ijbm.5000289.

PMID:
28777432
11.

Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance.

Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R, Hamilton G.

Sci Rep. 2017 Jul 13;7(1):5337. doi: 10.1038/s41598-017-05562-z.

12.

EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs.

Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, Pecha N, Mandorfer M, Pils D, Brisson AR, Zeillinger R, Lim SK.

Dis Markers. 2017;2017:9653194. doi: 10.1155/2017/9653194. Epub 2017 May 16.

13.

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.

Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T.

Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 3.

14.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

15.

Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.

Watrowski R, Heinze G, Jäger C, Forster J, Zeillinger R.

Tumour Biol. 2016 Sep;37(9):12079-12087. Epub 2016 May 20.

PMID:
27207344
16.

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.

Svoboda M, Meshcheryakova A, Heinze G, Jaritz M, Pils D, Castillo-Tong DC, Hager G, Thalhammer T, Jensen-Jarolim E, Birner P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Zimmermann P, Zeillinger R, Mechtcheriakova D.

BMC Genomics. 2016 Aug 16;17(1):643. doi: 10.1186/s12864-016-3001-y.

17.

Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64].

Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I.

Eur J Cancer. 2016 Jun;60:226. doi: 10.1016/j.ejca.2016.03.007. Epub 2016 Apr 19. No abstract available.

PMID:
27106403
18.

Statistical controversies in clinical research: the importance of importance.

Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M.

Ann Oncol. 2016 Jul;27(7):1185-9. doi: 10.1093/annonc/mdw159. Epub 2016 Apr 6.

PMID:
27052655
19.

Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.

Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI.

Anticancer Res. 2016 Mar;36(3):1015-22.

PMID:
26976992
20.

Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies.

Kuessel L, Kasimir-Bauer S, Zeillinger R, Pateisky P, Ott J, Zeisler H, Birdir C.

Hypertens Pregnancy. 2016 Aug;35(3):323-9. doi: 10.3109/10641955.2016.1143487. Epub 2016 Mar 1.

PMID:
26930176
21.

Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.

Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R.

Cell Adh Migr. 2016 Jul 3;10(4):360-7. doi: 10.1080/19336918.2016.1155019. Epub 2016 Feb 26.

22.

Biclustering strategies for genetic marker selection in gynecologic tumor cell lines.

Alevyzaki A, Sfakianakis S, Bei ES, Obermayr E, Zeillinger R, Fotiadis D, Zervakis M.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:1430-1433. doi: 10.1109/EMBC.2016.7590977.

PMID:
28324944
23.

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.

Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.

Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.

PMID:
26693899
24.

Association of HER2 codon 655 polymorphism with ovarian cancer.

Watrowski R, Castillo-Tong DC, Schuster E, Fischer MB, Speiser P, Zeillinger R.

Tumour Biol. 2016 Jun;37(6):7239-44. doi: 10.1007/s13277-015-4609-2. Epub 2015 Dec 14.

PMID:
26666819
25.

HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.

Watrowski R, Castillo-Tong DC, Wolf A, Schuster E, Fischer MB, Speiser P, Zeillinger R.

Anticancer Res. 2015 Dec;35(12):6667-70.

PMID:
26637882
26.

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.

Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, Vergote I, Heitz F, Sehouli J, Kinde I, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Speiser P, Zeillinger R.

J Clin Oncol. 2015 Dec 20;33(36):4293-300. doi: 10.1200/JCO.2015.61.3083. Epub 2015 Nov 9.

27.

HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.

Watrowski R, Castillo-Tong DC, Wolf A, Schuster E, Fischer MB, Speiser P, Zeillinger R.

Anticancer Res. 2015 Nov;35(11):5901-4.

PMID:
26504013
28.

Simple laboratory score improves the preoperative diagnosis of adnexal mass.

Watrowski R, Zeillinger R.

Tumour Biol. 2016 Apr;37(4):4343-9. doi: 10.1007/s13277-015-4280-7. Epub 2015 Oct 23.

PMID:
26499778
29.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
30.

The 811 C/T polymorphism in the 3' untranslated region of the selenoprotein 15-kDa (Sep15) gene and breast cancer in Caucasian women.

Watrowski R, Castillo-Tong DC, Fabjani G, Schuster E, Fischer M, Zeillinger R.

Tumour Biol. 2016 Jan;37(1):1009-15. doi: 10.1007/s13277-015-3847-7. Epub 2015 Aug 12.

PMID:
26264612
31.

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.

Auer K, Bachmayr-Heyda A, Aust S, Sukhbaatar N, Reiner AT, Grimm C, Horvat R, Zeillinger R, Pils D.

Oncotarget. 2015 Jul 10;6(19):17261-75.

32.

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.

Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.

Cancer Lett. 2015 Jul 1;362(2):218-28. doi: 10.1016/j.canlet.2015.03.040. Epub 2015 Apr 8.

33.

Circulating tumor cells in small cell lung cancer: ex vivo expansion.

Hamilton G, Burghuber O, Zeillinger R.

Lung. 2015 Jun;193(3):451-2. doi: 10.1007/s00408-015-9725-7. Epub 2015 Mar 29. No abstract available.

PMID:
25821178
34.

Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues.

Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Pils D.

Sci Rep. 2015 Jan 27;5:8057. doi: 10.1038/srep08057.

35.

Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.

Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, Castillo-Tong DC, Zeillinger R, Lambrechts S, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I.

Gynecol Oncol. 2014 Dec;135(3):415-22. doi: 10.1016/j.ygyno.2014.09.014. Epub 2014 Oct 2.

PMID:
25281495
36.

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium.

Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J.

Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014.

37.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.

PMID:
24889916
38.

Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.

Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D.

Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67.

39.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

40.

Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasia.

Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S, Speiser P, Zeillinger R, Heinze G, Grimm C.

Dis Markers. 2013;35(2):79-84. doi: 10.1155/2013/368732. Epub 2013 Jul 28.

41.

Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulate expression of atherogenic LR11 in human coronary artery endothelium.

Bajari TM, Winnicki W, Gensberger ET, Scharrer SI, Regele H, Aumayr K, Kopecky C, Gmeiner BM, Hermann M, Zeillinger R, Sengölge G.

Thromb Haemost. 2014 Feb;111(2):323-32. doi: 10.1160/TH12-12-0924. Epub 2013 Nov 28.

PMID:
24284991
42.

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.

Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011. Epub 2013 Oct 28.

PMID:
24176298
43.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.

Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.

BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.

44.

eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women.

Groten T, Schleussner E, Lehmann T, Reister F, Holzer B, Danso KA, Zeillinger R.

Arch Gynecol Obstet. 2014 Mar;289(3):581-93. doi: 10.1007/s00404-013-2991-9. Epub 2013 Sep 8.

PMID:
24013430
45.

Association of myeloperoxidase with ovarian cancer.

Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.

Tumour Biol. 2014 Jan;35(1):141-8. doi: 10.1007/s13277-013-1017-3. Epub 2013 Jul 27.

46.

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.

Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20.

PMID:
23877013
47.

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.

Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J.

J Ovarian Res. 2013 Jun 28;6(1):42. doi: 10.1186/1757-2215-6-42.

48.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.

Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.

BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.

49.

PP057. ENOSI4 and EPHX1 polymorphisms affect maternal susceptibility topreeclampsia - Analysis of five polymorphisms predisposing tocardiovascular disease in 279 caucasian and 241 african women.

Groten T, Schlembach D, Zeillinger R, Holzer B.

Pregnancy Hypertens. 2013 Apr;3(2):88. doi: 10.1016/j.preghy.2013.04.084. Epub 2013 Jun 6.

PMID:
26105914
50.

Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.

Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC.

Int J Gynecol Pathol. 2013 May;32(3):269-76. doi: 10.1097/PGP.0b013e31826a63f8.

PMID:
23518910

Supplemental Content

Loading ...
Support Center